Clinical Trial Update: Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study comparing two 75 mg clopidogrel tablet formulations to the reference tablet in healthy subjects; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease

Drugs mentioned

• CLOPIDOGREL (CLOPIDOGREL)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cardiovascular Disease | Phase 1 | Status: COMPLETED